GSK and SBP Group partner to advance bepirovirsen launch in China

GSK has partnered with SBP Group, via its subsidiary CTTQ, to expedite the launch of bepirovirsen for chronic hepatitis B patients in China. CTTQ will manage importation, distribution, hospital access, and all promotional and non-promotional activities for bepirovirsen. GSK will retain its role as marketing authorisation holder and oversee regulatory activities. Credit: MAXSHOT.PL / Shutterstock.com. GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to expedite the launch of bepirovirsen for chronic hepatitis B (CHB) patients in mainland China. The move leverages CTTQ’s extensive reach and portfolio in liver disease,…

Source: Pharmaceutical Technology